Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis

References

• Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–2686.
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. Ca Cancer J Clin. 2018;68:471–487.
   PubMed Web of Science ®Google Scholar
• Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–597.
   PubMed Web of Science ®Google Scholar
• Frilling A, Clift AK, Braat AJAT, et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB (Oxford). 2019;21(7):773–783.
   PubMed Web of Science ®Google Scholar
• Jones NB, Shah MH, Bloomston M. Liver-directed therapies in patients with advanced neuroendocrine tumors. JNCCN. 2012;10(6):765–774.
   Google Scholar
• Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):68–81.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 1.2019. Neuroendocrine and Adrenal Tumors. Published by the National Comprehensive Cancer Network, Plymouth Meeting, PA, USA. [2019; cited 2019 Oct 4]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine_blocks.pdf.
   Google Scholar
• Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol. 2011;29(7):934–943.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–977.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller HH, Schade-Brittinger C, et al.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663.
   PubMed Web of Science ®Google Scholar
• Rinke A, Wittenberg M, Schade-Brittinger C, et al.; PROMID Study Group. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long term survival. Neuroendocrinology. 2017;104:26–32.
   PubMed Web of Science ®Google Scholar
• Gurusamy KS, Ramamoorthy R, Sharma D, et al. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009;2009(2):CD007060.
   PubMed Web of Science ®Google Scholar
• Glanville J, Lefebvre C, Wright K, editors. The InterTASC information specialists’ sub-group search filter resource. York, UK, 2019. 2008; [cited 2020 Jul 9]. Available from https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home
   Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. London, UK: The Cochrane Collaboration; [Updated 2011 Mar; cited 2020 Jul 9]. Available from: https://www.handbook.cochrane.org
   Google Scholar
• University of Texas. Health Science Center at Houston. School of public health. Search filters for various databases: ovid medline. [2019; cited 2019 Jul 22]. Available from: http://libguides.sph.uth.tmc.edu/search_filters/ovid_medline_filters.
   Google Scholar
• Covalence Research Ltd. Sourcerer. London, UK. [2019; cited 2020 Jul 9]. Available from: https://sourcerer.pro.
   Google Scholar
• National Institute for Health and Care Excellence (2013) Selective internal radiation therapy for primary hepatocellular carcinoma. [cited 2020 Jul 9]. Available from: https://www.nice.org.uk/guidance/IPG460
   Google Scholar
• Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–1316.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413.
   Google Scholar
• Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21(4):607–611.
   Google Scholar
• Guisan A, Zimmermann NE. Predictive habitat distribution models in ecology. Ecol Model. 2000;135:147–186.
   Web of Science ®Google Scholar
• Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–279.
   PubMed Web of Science ®Google Scholar
• King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113(5):921–929.
   PubMed Web of Science ®Google Scholar
• Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19(1):145–151.
   PubMed Web of Science ®Google Scholar
• Kalinowski M, Dressler M, König A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79(3):137–142.
   PubMed Web of Science ®Google Scholar
• Saxena A, Chua TC, Bester L, et al. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251(5):910–916.
   PubMed Web of Science ®Google Scholar
• Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97(4):537–543.
   PubMed Web of Science ®Google Scholar
• Rajekar H, Bogammana K, Stubbs RS. Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol. 2011;2011:404916. https://www.hindawi.com/journals/ijh/2011/404916/
   PubMedGoogle Scholar
• Lacin S, Oz I, Ozkan E, et al. Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response. Cancer Biother Radiopharm. 2011;26(5):631–637.
   PubMed Web of Science ®Google Scholar
• Jahangir KS, Majoria R, Hagan J, et al. Hepatic artery radioembolization (HARE) in the management of progressive metastatic neuroendocrine tumors (NETs): A survival and biochemical response analysis in geriatric (G) and young (Y) populations. J Clin Oncol. 2011;29(15):e19727.
   Google Scholar
• Arslan N, Emi M, Alagöz E, et al. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center. Vojnosanit Pregl. 2011;68(4):341–348.
   PubMed Web of Science ®Google Scholar
• Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012;35(2):334–342.
   PubMed Web of Science ®Google Scholar
• McElmurray JH, Bream PR, Grzeszczak E, et al. Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. J Vasc Interv Radiol. 2012;23(6):853.e16.
   Google Scholar
• Ezziddin S, Meyer C, Kahancova S, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Friedman ML, Kim AS, et al. Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers. Pancreas. 2013;42(2):358–360.
   PubMed Web of Science ®Google Scholar
• Kharoti Y, Ahuja C, Farsad K, et al. Clinical and imaging response in neuroendocrine hepatic metastasis treated with Y-90 radioembolization. J Vasc Interv Radiol. 2013;24(4):S151.
   PubMedGoogle Scholar
• Peker A, Çiçek O, Soydal Ç, et al. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. 2015;21(1):54–59.
   PubMed Web of Science ®Google Scholar
• Ceelen F, Theisen D, de Albéniz XG, et al. Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? J Magn Resonan Imag. 2015;41(2):361–368.
   PubMed Web of Science ®Google Scholar
• Boni G, Bargellini I, Tredici M, et al. Safety and efficacy of transarterial Y-90 radioembolisation for liver metastases of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2015;42(Suppl 1):S747.
   Google Scholar
• Ludwig JM, Ambinder EM, Ghodadra A, et al. Lung shunt fraction prior to yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis. Cardiovasc Intervent Radiol. 2016;39(7):1007–1014.
   PubMed Web of Science ®Google Scholar
• Filippi L, Scopinaro F, Pelle G, et al. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur J Nucl Med Mol Imag. 2016;43(3):432–440.
   PubMed Web of Science ®Google Scholar
• Barbier CE, Garske-Román U, Sandström M, et al. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imag. 2016;43(8):1425–1431.
   PubMed Web of Science ®Google Scholar
• Chansanti O, Jahangiri Y, Matsui Y, et al. Tumor dose response in yttrium-90 resin microsphere embolization for neuroendocrine liver metastases: a tumor-specific analysis with dose estimation using SPECT-CT. J Vasc Intervent Radiol. 2017;28: 1528–1535.
   PubMed Web of Science ®Google Scholar
• Tomozawa Y, Jahangiri Y, Pathak P, et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29(6):858–865.
   PubMed Web of Science ®Google Scholar
• Elf AK, Andersson M, Henrikson O, et al. Radioembolization versus bland embolization for hepatic metastases from small intestinal neuroendo- crine tumors: short-term results of a randomized clinical trial. World J Surg. 2018;42:506–513.
   PubMed Web of Science ®Google Scholar
• Braat AJAT, Kappadath SC, Ahmadzadehfar H, et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413–425.
   PubMed Web of Science ®Google Scholar
• Jia Z, Paz-Fumagalli R, Frey G, et al. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. J Gastroenterol Hepatol. 2017;32:1617–1623.
   PubMed Web of Science ®Google Scholar
• Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27:4995–5005.
   PubMed Web of Science ®Google Scholar
• Fan KY, Wild AT, Halappa VG, et al. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials. 2016;50:143–149.
   PubMed Web of Science ®Google Scholar
• Fidelman N, Kerlan RK Jr, Hawkins RA, et al. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016;7:860–874.
   PubMed Web of Science ®Google Scholar
• Singla S, LeVea CM, Pokuri VK, et al. Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. J Gastrointest Oncol. 2016;7(3):441–448.
   PubMed Web of Science ®Google Scholar
• Engelman ES, Leon-Ferre R, Naraev BG, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014;43:219–225.
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Geschwind JF, Mulcahy MF, et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013;49(15):3122–3130.
   PubMed Web of Science ®Google Scholar
• Shaheen M, Hassanain M, Aljiffry M, et al. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012;14(1):60–66.
   PubMed Web of Science ®Google Scholar
• Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887–894.
   PubMed Web of Science ®Google Scholar
• Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247(6):1029–1035.
   PubMed Web of Science ®Google Scholar
• Kim HC. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2017;23(2):109–114.
   PubMed Web of Science ®Google Scholar
• Adcock CS, Florez E, Zand KA, et al. Assessment of treatment response following yttrium-90 transarterial radioembolization of liver malignancies. Cureus. 2018;10(6):e2895.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35(3):421–430.
   PubMed Web of Science ®Google Scholar
• Basciano CA, Kleinstreuer C, Kennedy AS. Computational fluid dynamics modeling of 90Y microspheres in human hepatic tumors. J Nucl Med Radiat Ther. 2011;2(1):112.
   Google Scholar
• Sommer WH, Ceelen F, García-Albéniz X, et al. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013;23(11):3094–3103.
   PubMed Web of Science ®Google Scholar
• Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–1563.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. SIR-Spheres for treating inoperable hepatocellular carcinoma: medtech innovation briefing 63. London, UK. [2016; cited 2020 Jul 9]. Available from: https://www.nice.org.uk/advice/MIB63
   Google Scholar
• National Institute for Health and Care Excellence. TheraSphere for treating operable and inoperable hepatocellular carcinoma: medtech innovation briefing 62. London, UK. [2016; cited 2020 Jul 9]. Available from: https://www.nice.org.uk/advice/MIB62
   Google Scholar
• Schwarzer G, Chemaitelly H, Abu-Raddad LJ, et al. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10(3):476–483.
   PubMed Web of Science ®Google Scholar
• Ter-Minassian M, Zhang S, Brooks NV, et al. Association between tumor progression endpoints and overall survival in patients with advanced neuroendocrine tumors. Oncologist. 2017;22(2):165–172.
   PubMed Web of Science ®Google Scholar
• Imaoka H, Sasaki M, Takahashi H, et al. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms. Endocr Relat Cancer. 2017;24(9):475–483.
   PubMed Web of Science ®Google Scholar
• Imaoka H, Sasaki M, Takahashi H, et al. Alternate endpoints for Phase II trials in advanced neuroendocrine tumors. Oncologist. 2019;24(1):47–53.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Prajapati HJ, Spivey JR, Hanish SI, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965–973.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. Food and Drug Administration; Silver Spring, MD, USA; [2018; cited 2019 Oct 24]. Available from: https://www.fda.gov/media/71195/download.
   Google Scholar
• European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. European Medicines Agency; Amsterdam, Netherlands; [2018; cited 2019 Oct 24]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf
   Google Scholar
• Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218–5224.
   PubMed Web of Science ®Google Scholar
• Delea TE, Khuu A, Heng DY, et al. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer. 2012;107(7):1059–1068.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al.; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823.
   PubMed Web of Science ®Google Scholar
• Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008;24(4):371–383.
   PubMed Web of Science ®Google Scholar
• Su YK, Mackey RV, Riaz A, et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol. 2017;28(11):1520–1526.
   PubMed Web of Science ®Google Scholar